- Conditions
- Asthma
- Interventions
- Placebo, MEDI9929 70 mg, MEDI9929 210 mg, MEDI9929 280 mg
- Drug
- Lead sponsor
- MedImmune LLC
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 584 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2017
- U.S. locations
- 18
- States / cities
- Los Angeles, California • Miami, Florida • Oviedo, Florida + 12 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–5
of 5
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Cat Allergy, Cat Hypersensitivity
- Interventions
- AMG 157, Cat Immunotherapy, Cat Immunotherapy Placebo, AMG 157 Placebo
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 9
- States / cities
- Los Angeles, California • Denver, Colorado • Chicago, Illinois + 5 more
- Conditions
- Asthma
- Interventions
- Tezepelumab, Placebo
- Biological · Other
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 5 Years to 11 Years
- Enrollment
- 231 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2030
- U.S. locations
- 30
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 26 more
- Conditions
- Atopic Dermatitis
- Interventions
- Tezepelumab, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 251 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 16
- States / cities
- Fountain Valley, California • Santa Monica, California • Alpharetta, Georgia + 12 more
- Conditions
- Chronic Spontaneous Urticaria
- Interventions
- Tezepelumab Dose 1, Tezepelumab Dose 2, Omalizumab, Placebo
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 25
- States / cities
- Birmingham, Alabama • Fountain Valley, California • Laguna Niguel, California + 21 more